Amicus Therapeutics CEO Bradley Campbell is set to succeed Eric Dube as President and CEO of Travere Therapeutics, effective Dec. 1. The leadership change reflects the end of Dube’s eight-year tenure at the rare disease company. The transition is notable for Travere’s strategic continuity as it navigates a competitive rare-disease landscape where governance stability can affect partnerships, clinical timelines, and commercialization decisions. Alongside the CEO shift, the announcement also named board leadership updates for other private biotechs, underscoring ongoing management churn across the sector. For investors and collaborators, leadership continuity at mid- to late-stage rare disease biotechs is a key risk factor, and the move aligns Travere with an operator coming from an acquired Amicus platform.